| Literature DB >> 27538847 |
Jan Zernicke1, Claudia Kedor2, Angela Müller3, Gerd-Rüdiger Burmester2, Anett Reißhauer3, Eugen Feist2.
Abstract
BACKGROUND: Physical exercises and physiotherapy are of great importance for maintenance of joint function in patients with rheumatoid arthritis (RA). However, many RA patients complain about problems to receive prescriptions or have a lack of access to physiotherapy. Recent reports have shown positive effects of the Wii game console on physical and psychosocial conditions of patients with other underlying diseases. The primary objectives of this prospective controlled pilot study were to investigate feasibility and patients' assessment using an animated home-based exercise program.Entities:
Keywords: Exercises; Patient perspective; Physical therapy; Rehabilitation; Rheumatoid arthritis; Wii® game console
Mesh:
Year: 2016 PMID: 27538847 PMCID: PMC4990861 DOI: 10.1186/s12891-016-1208-3
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Baseline characteristics of patients
| Total | Patients starting with animated exercise program (Wii console)a1 | Patients starting with conventional home-based physical exercisesa1 | |
|---|---|---|---|
| Number of patients, n | 30 | 15 | 15 |
| Age (years), mean (SD) | 56 (±9) | 52 (±8) | 59 (±9) |
| Age (years), min. | 34 | 34 | 45 |
| Age (years), max. | 69 | 65 | 69 |
| Age > 60 years, n (%) | 11 (37 %) | 3 (20 %) | 8 (53 %) |
| Age 50 – 60 years, n (%) | 10 (33 %) | 7 (47 %) | 3 (20 %) |
| Age <50 years, n (%) | 9 (30 %) | 5 (33 %) | 4 (27 %) |
| Female, n (%) | 25 (83 %) | 10 (67 %) | 15 (100 %) |
| Disease duration (years), mean (SD) | 13 (±9) | 10 (±7) | 16 (±9) |
| disease duration (years), max. | 36 | 26 | 36 |
| disease duration (years), min. | 1 | 1 | 1 |
| DAS28, mean (SD) | 2.8 (±1.2) | 3.0 (±1.5) | 2.6 (±0.9) |
| DAS28 score, max. | 5.3 | 5.3 | 4.4 |
| DAS28 score, min. | 0.5 | 0.9 | 0.5 |
| HAQ-DI score, mean (SD) | 0.85 (±0.53) | 0.72 (±0.52) | 0.98 (±0.51) |
| HAQ-DI score, max. | 1.75 | 1.75 | 1.63 |
| HAQ-DI score, min. | 0.00 | 0.00 | 0.00 |
| Patient’s VAS disease activity, mm | 17 | 16 | 18 |
| Current biological DMARD therapy | |||
| Rituximab, n (%) | 12 (40 %) | 7 (47 %) | 5 (33 %) |
| Tocilizumab, n (%) | 10 (33 %) | 5 (33 %) | 5 (33 %) |
| Abatacept, n (%) | 5 (17 %) | 2 (13 %) | 3 (20 %) |
| Etanercept, n (%) | 2 (6 %) | 1 (7 %) | 1 (7 %) |
| Certolizumab, n (%) | 1 (3 %) | 0 (0 %) | 1 (7 %) |
| Previous biological DMARD therapy | |||
| Rituximab, n (%) | 4 (13 %) | 2 (13 %) | 2 (13 %) |
| Tocilizumab, n (%) | 3 (10 %) | 1 (7 %) | 2 (13 %) |
| Abatacept, n (%) | 2 (6 %) | 1 (7 %) | 1 (7 %) |
| Etanercept, n (%) | 10 (33 %) | 7 (47 %) | 3 (20 %) |
| Certolizumab, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
| Golimumab, n (%) | 1 (3 %) | 0 (0 %) | 1 (7 %) |
| Secukinumab, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
| Infliximab, n (%) | 6 (20 %) | 2 (13 %) | 4 (27 %) |
| Anakinra, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
| ≥ 3 previous biological DMARD’s, n | 7 (23 %) | 4 (27 %) | 3 (20 %) |
| ≥ 2 previous biological DMARD’s, n | 8 (27 %) | 4 (27 %) | 4 (27 %) |
| only 1 previous biological DMARD, n | 6 (20 %) | 2 (13 %) | 4 (27 %) |
a1 with a cross-over to the other treatment arm after 12 weeks SD, standard deviation; min, minimum; max, maximum; HAQ-DI, health assessment questionnaire disability index; DAS28, disease activity score using the 28 joint count; DMARD, disease modifying anti-rheumatic drug; VAS, Visual analogue scale
Fig. 1Patients’ response to the exercise program
Fig. 2Patients reported outcomes according to interview analysis
Fig. 3Patients reported advantages and criticism according to interview analysis
Fig. 4Results of muscle strength measurement
Fig. 5Results of 6-minute walk test